Floatz logo

Docetaxel

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Shanghai Henlius BiotechSmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

54 Active assets in the Advanced or Metastatic Squamous Non-Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3BBB
Serplulimab
Shanghai Henlius Biotech
Phase 3BB
Pembrolizumab
Shanghai Henlius Biotech
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3BB
Tislelizumab
BeOne Medicines
Phase 3BB

View all 50 →

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →